Close Menu

A team from Spain, China, Switzerland, and the US report on potential treatment targets and resistance mechanisms in KRAS-mutated forms of lung adenocarcinoma. Using genetically engineered mouse model experiments, pharmacological experiments, and other approaches, the team highlighted the potential for curbing lung adenocarcinoma growth by targeting RAF1 as well as cyclin-dependent kinases downstream of the MAP-kinase signaling pathway in advanced tumors driven by KRAS and p53.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.